AURA · Aura Biosciences, Inc.

Track AURA — free

$7.00 +0.01 (+0.07%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$726.97M

103.70M

Up next

Next earnings call

Sep 18, 2026 Est · unconfirmed · in 1 wks

Latest filing: 10-Q

filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$131.01M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-14.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$67.84M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+63.5%

Year over year · more shares

Price change (1Y)

+8.5%

Trailing year

Short interest

6.0%

Latest settlement · 6.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +5%

above

Price vs 50-day avg −5%

below

RSI (14) 40

neutral

MACD trend Negative

52-week position 52%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −9%

trailing

6-month return +7%

trailing

YTD return +28%

this year

Relative strength −11%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+17% holders QoQ · +36 funds added

Insider flow Distributing

Net -$82.3K over 90 days · 100% sells

Short interest Rising

5.98% of float · ▲ +0.7% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

148 holders — near 3-yr high, broad support

Squeeze score 64

elevated · 0–100

Fundamentals

Poor

EPS growth −1%

Y/Y

Free cash flow $-85.2M

Quant / Vol

risk profile

Very High

Volatility 58%

annualized · 1-yr

Max drawdown −31%

past year

ATR 5.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+5% Bullish

Price vs 50-day avg

−5% Neutral

RSI (14)

40 Neutral

MACD trend

Negative Bearish

52-week position

52% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+17% holders QoQ · +36 funds added

Insider flow Distributing

Net -$82.3K over 90 days · 100% sells

Short interest Rising

5.98% of float · ▲ +0.7% MoM · 6.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

148 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $7 · 52% Range high $9

vs 200-day avg +5% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AURA Aura Biosciences, Inc. this stock	$726.97M	+28.3%	—	—	6.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$81.67B	+1.2%	+20.8%	19.6	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
CSLLY Csl Ltd	$57.41B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

148

% held: 92.1%
Net QoQ: +44.3M sh
Top holder: TCG Crossover Management,…

Held Float

View

Held by Funds

Fund positions

138

View

Short & Settlement

Short Interest Rising

Shares short

6.2M

Days to cover: 6.4d
Change: +44.6K sh

View

Short Volume

Short vol %

37%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

4.4K

Value: $31.4K
As of: Aug 6, 2026

View

Off-Exchange

Off-exchange %

37.7%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$82.3K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-106.2M

EPS diluted: $-1.76

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 11, 2026
This year: 14

View

Proposed Sales

Value

$82.3K

Shares: 12.8K
Filed: Jun 16, 2026

View

Exempt Offerings

Offering

$80.5M

Filed: Apr 6, 2021

View

Earnings & Events

Earnings Calls

Last call

May 27, 2026

View

Performance

	5D	20D	120D	MTD	YTD
AURA	-5.1%	-8.6%	+6.8%	-2.6%	+28.4%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-3.9%	-6.8%	-11.1%	-2.2%	+16.3%

Key facts CIK 1501796 CUSIP 05153U107 13F (30d) 87 filings 87 filers Visit website Investor relations

AURA · Aura Biosciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance